Abstract
Prognosis in cirrhosis is highly variable depending on the stage, with one-year mortality ranging from 1 to 57 %. Clinicians therefore should focus on an early diagnosis of advanced liver disease before decompensation occurs. Noninvasive fibrosis tests, such as transient elastography, together with hepatic venous pressure gradient (HVPG) and quantitative fibrosis assessment using CPA, can be used to subclassify patients with cirrhosis and predict clinical decompensation. HVPG values above 10 mmHg and/or transient elastography values >20 KPa are associated with increased risk of decompensation. The management of patients with cirrhosis should therefore change to preventing the advent of all complications while in the compensated phase. Safe, widely available, and relatively inexpensive treatment regimens seem to have beneficial effects on reduction of portal pressure, prevention of complications, regression of fibrosis, and improvement in survival. Such drugs include b-blockers, statins, metformin, nonabsorbable antibiotics, and anticoagulants either alone or in combination. The potential effect of these drugs should be investigated in phase III randomized controlled trials. In the current era, cirrhosis should be regarded as treatable and potentially reversible with currently available therapy and not an irreversible disease that leads inevitably to liver transplantation or death.
Keywords
- Portal Hypertension
- Portal Vein Thrombosis
- Variceal Bleeding
- Liver Stiffness
- Spontaneous Bacterial Peritonitis
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.
This is a preview of subscription content, log in via an institution.
Buying options
Tax calculation will be finalised at checkout
Purchases are for personal use only
Learn about institutional subscriptionsReferences
Tsochatzis EA, Bosch J, Burroughs AK (2014) Liver cirrhosis. Lancet 383(9930):1749–1761
D'Amico G, Morabito A, Pagliaro L, Marubini E (1986) Survival and prognostic indicators in compensated and decompensated cirrhosis. Dig Dis Sci 31(5):468–475
D'Amico G, Garcia-Tsao G, Pagliaro L (2006) Natural history and prognostic indicators of survival in cirrhosis: a systematic review of 118 studies. J Hepatol 44(1):217–231
Arvaniti V, D'Amico G, Fede G, Manousou P, Tsochatzis E, Pleguezuelo M et al (2010) Infections in patients with cirrhosis increase mortality four-fold and should be used in determining prognosis. Gastroenterology 139(4):1246–1256, 1256e1–1256e5
Ripoll C, Groszmann R, Garcia-Tsao G, Grace N, Burroughs A, Planas R et al (2007) Hepatic venous pressure gradient predicts clinical decompensation in patients with compensated cirrhosis. Gastroenterology 133(2):481–488
Blasco A, Forns X, Carrion JA, Garcia-Pagan JC, Gilabert R, Rimola A et al (2006) Hepatic venous pressure gradient identifies patients at risk of severe hepatitis C recurrence after liver transplantation. Hepatology 43(3):492–499
Ripoll C, Groszmann RJ, Garcia-Tsao G, Bosch J, Grace N, Burroughs A et al (2009) Hepatic venous pressure gradient predicts development of hepatocellular carcinoma independently of severity of cirrhosis. J Hepatol 50(5):923–928
Garcia-Tsao G, Groszmann RJ, Fisher RL, Conn HO, Atterbury CE, Glickman M (1985) Portal pressure, presence of gastroesophageal varices and variceal bleeding. Hepatology 5(3):419–424
Moitinho E, Escorsell A, Bandi JC, Salmeron JM, Garcia-Pagan JC, Rodes J et al (1999) Prognostic value of early measurements of portal pressure in acute variceal bleeding. Gastroenterology 117(3):626–631
Abraldes JG, Villanueva C, Banares R, Aracil C, Catalina MV, Garci APJC et al (2008) Hepatic venous pressure gradient and prognosis in patients with acute variceal bleeding treated with pharmacologic and endoscopic therapy. J Hepatol 48(2):229–236
D'Amico G, Garcia-Pagan JC, Luca A, Bosch J (2006) Hepatic vein pressure gradient reduction and prevention of variceal bleeding in cirrhosis: a systematic review. Gastroenterology 131(5):1611–1624
Albillos A, Banares R, Gonzalez M, Ripoll C, Gonzalez R, Catalina MV et al (2007) Value of the hepatic venous pressure gradient to monitor drug therapy for portal hypertension: a meta-analysis. Am J Gastroenterol 102(5):1116–1126
Ripoll C (2007) Hepatic venous pressure gradient and outcomes in cirrhosis. J Clin Gastroenterol 41(Suppl 3):S330–S335
Villanueva C, Lopez-Balaguer JM, Aracil C, Kolle L, Gonzalez B, Minana J et al (2004) Maintenance of hemodynamic response to treatment for portal hypertension and influence on complications of cirrhosis. J Hepatol 40(5):757–765
Hernandez-Gea V, Aracil C, Colomo A, Garupera I, Poca M, Torras X et al (2012) Development of ascites in compensated cirrhosis with severe portal hypertension treated with beta-blockers. Am J Gastroenterol 107(3):418–427
Bruix J, Castells A, Bosch J, Feu F, Fuster J, Garcia-Pagan JC et al (1996) Surgical resection of hepatocellular carcinoma in cirrhotic patients: prognostic value of preoperative portal pressure. Gastroenterology 111(4):1018–1022
Calvaruso V, Burroughs AK, Standish R, Manousou P, Grillo F, Leandro G et al (2009) Computer-assisted image analysis of liver collagen: relationship to Ishak scoring and hepatic venous pressure gradient. Hepatology 49(4):1236–1244
Manousou P, Dhillon AP, Isgro G, Calvaruso V, Luong TV, Tsochatzis E et al (2011) Digital image analysis of liver collagen predicts clinical outcome of recurrent hepatitis C virus 1 year after liver transplantation. Liver Transpl 17(2):178–188
Tsochatzis E, Bruno S, Isgro G, Hall A, Theocharidou E, Manousou P et al (2014) Collagen proportionate area is superior to other histological methods for sub-classifying cirrhosis and determining prognosis. J Hepatol 60(5):948–954
Calvaruso V, Dhillon AP, Tsochatzis E, Manousou P, Grillo F, Germani G et al (2012) Liver collagen proportionate area predicts decompensation in patients with recurrent hepatitis C virus cirrhosis after liver transplantation. J Gastroenterol Hepatol 27(7):1227–1232
Manousou P, Burroughs AK, Tsochatzis E, Isgro G, Hall A, Green A et al (2013) Digital image analysis of collagen assessment of progression of fibrosis in recurrent HCV after liver transplantation. J Hepatol 58(5):962–968
Huang Y, de Boer WB, Adams LA, MacQuillan G, Bulsara MK, Jeffrey GP (2014) Image analysis of liver biopsy samples measures fibrosis and predicts clinical outcome. J Hepatol 61(1):22–27
Castera L, Pinzani M, Bosch J (2012) Non invasive evaluation of portal hypertension using transient elastography. J Hepatol 56(3):696–703
Vizzutti F, Arena U, Romanelli RG, Rega L, Foschi M, Colagrande S, Petrarca A, Moscarella S, Belli G, Zignego AL, Marra F, Laffi G, Pinzani M (2007) Liver stiffness measurement predicts severe portal hypertension in patients with HCV-related cirrhosis. Hepatology 45(5):1290–1297
Robic MA, Procopet B, Metivier S, Peron JM, Selves J, Vinel JP et al (2011) Liver stiffness accurately predicts portal hypertension related complications in patients with chronic liver disease: a prospective study. J Hepatol 55(5):1017–1024
Singh S, Fujii LL, Murad MH, Wang Z, Asrani SK, Ehman RL et al (2013) Liver stiffness is associated with risk of decompensation, liver cancer, and death in patients with chronic liver diseases: a systematic review and meta-analysis. Clin Gastroenterol Hepatol 11(12):1573–1584e1-2; quiz e88–e89
Vergniol J, Boursier J, Coutzac C, Bertrais S, Foucher J, Angel C et al (2014) Evolution of noninvasive tests of liver fibrosis is associated with prognosis in patients with chronic hepatitis C. Hepatology 60(1):65–76
Sterling RK, Lissen E, Clumeck N, Sola R, Correa MC, Montaner J et al (2006) Development of a simple noninvasive index to predict significant fibrosis in patients with HIV/HCV coinfection. Hepatology 43(6):1317–1325
Tsochatzis EA, Bosch J, Burroughs AK (2012) New therapeutic paradigm for patients with cirrhosis. Hepatology 56(5):1983–1992
Tsochatzis EA, Bosch J, Burroughs AK (2014) Future treatments of cirrhosis. Expert Rev Gastroenterol Hepatol 8(5):571–581
Berzigotti A, Garcia-Tsao G, Bosch J, Grace ND, Burroughs AK, Morillas R et al (2011) Obesity is an independent risk factor for clinical decompensation in patients with cirrhosis. Hepatology 54(2):555–561
Goh GB, Chow WC, Wang R, Yuan JM, Koh WP (2014) Coffee, alcohol and other beverages in relation to cirrhosis mortality: the Singapore Chinese Health Study. Hepatology 60(2):661–669
Freedman ND, Everhart JE, Lindsay KL, Ghany MG, Curto TM, Shiffman ML et al (2009) Coffee intake is associated with lower rates of liver disease progression in chronic hepatitis C. Hepatology 50(5):1360–1369
Hu G, Tuomilehto J, Pukkala E, Hakulinen T, Antikainen R, Vartiainen E et al (2008) Joint effects of coffee consumption and serum gamma-glutamyltransferase on the risk of liver cancer. Hepatology 48(1):129–136
Lewis JH, Mortensen ME, Zweig S, Fusco MJ, Medoff JR, Belder R et al (2007) Efficacy and safety of high-dose pravastatin in hypercholesterolemic patients with well-compensated chronic liver disease: results of a prospective, randomized, double-blind, placebo-controlled, multicenter trial. Hepatology 46(5):1453–1463
Simon TG, King LY, Zheng H, Chung RT (2015) Statin use is associated with a reduced risk of fibrosis progression in chronic hepatitis C. J Hepatol 62(1):18–23
Abraldes JG, Albillos A, Banares R, Turnes J, Gonzalez R, Garcia-Pagan JC et al (2009) Simvastatin lowers portal pressure in patients with cirrhosis and portal hypertension: a randomized controlled trial. Gastroenterology 136(5):1651–1658
El-Serag HB, Johnson ML, Hachem C, Morgana RO (2009) Statins are associated with a reduced risk of hepatocellular carcinoma in a large cohort of patients with diabetes. Gastroenterology 136(5):1601–1608
Singh S, Singh PP, Singh AG, Murad MH, Sanchez W (2013) Statins are associated with a reduced risk of hepatocellular cancer: a systematic review and meta-analysis. Gastroenterology 144(2):323–332
Singh S, Singh PP, Singh AG, Murad MH, Sanchez W (2013) Anti-diabetic medications and the risk of hepatocellular cancer: a systematic review and meta-analysis. Am J Gastroenterol 108(6):881–891; quiz 892
Chen HP, Shieh JJ, Chang CC, Chen TT, Lin JT, Wu MS et al (2013) Metformin decreases hepatocellular carcinoma risk in a dose-dependent manner: population-based and in vitro studies. Gut 62(4):606–615
Zhang X, Harmsen WS, Mettler TA, Kim WR, Roberts RO, Therneau TM et al (2014) Continuation of metformin use after a diagnosis of cirrhosis significantly improves survival of patients with diabetes. Hepatology 60(6):2008–2016
Nkontchou G, Cosson E, Aout M, Mahmoudi A, Bourcier V, Charif I et al (2011) Impact of metformin on the prognosis of cirrhosis induced by viral hepatitis C in diabetic patients. J Clin Endocrinol Metab 96(8):2601–2608
Garcia-Tsao G, Bosch J (2010) Management of varices and variceal hemorrhage in cirrhosis. N Engl J Med 362(9):823–832
Lo GH, Chen WC, Lin CK, Tsai WL, Chan HH, Chen TA et al (2008) Improved survival in patients receiving medical therapy as compared with banding ligation for the prevention of esophageal variceal rebleeding. Hepatology 48(2):580–587
Senzolo M, Cholongitas E, Burra P, Leandro G, Thalheimer U, Patch D et al (2009) beta-Blockers protect against spontaneous bacterial peritonitis in cirrhotic patients: a meta-analysis. Liver Int 29(8):1189–1193
Reiberger T, Ferlitsch A, Payer BA, Mandorfer M, Heinisch BB, Hayden H et al (2013) Non-selective betablocker therapy decreases intestinal permeability and serum levels of LBP and IL-6 in patients with cirrhosis. J Hepatol 58(5):911–921
Mandorfer M, Bota S, Schwabl P, Bucsics T, Pfisterer N, Kruzik M et al (2014) Nonselective beta blockers increase risk for hepatorenal syndrome and death in patients with cirrhosis and spontaneous bacterial peritonitis. Gastroenterology 146(7):1680–1690.e1
Bass NM, Mullen KD, Sanyal A, Poordad F, Neff G, Leevy CB et al (2010) Rifaximin treatment in hepatic encephalopathy. N Engl J Med 362(12):1071–1081
Vlachogiannakos J, Viazis N, Vasianopoulou P, Vafiadis I, Karamanolis DG, Ladas SD (2013) Long-term administration of rifaximin improves the prognosis of patients with decompensated alcoholic cirrhosis. J Gastroenterol Hepatol 28(3):450–455
Villa E, Camma C, Marietta M, Luongo M, Critelli R, Colopi S et al (2012) Enoxaparin prevents portal vein thrombosis and liver decompensation in patients with advanced cirrhosis. Gastroenterology 143(5):1253–1260e1-4
Tsochatzis EA, Bosch J, Burroughs AK (2010) Prolonging survival in patients with cirrhosis: old drugs with new indications. Gastroenterology 139(6):1813–1815.e1
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2016 Springer International Publishing Switzerland
About this paper
Cite this paper
Kalafateli, M., Tsochatzis, E.A. (2016). Defining Clinical Hints to Predict Decompensation and Altering Paradigm in Patients with Cirrhosis. In: de Franchis, R. (eds) Portal Hypertension VI. Springer, Cham. https://doi.org/10.1007/978-3-319-23018-4_11
Download citation
DOI: https://doi.org/10.1007/978-3-319-23018-4_11
Publisher Name: Springer, Cham
Print ISBN: 978-3-319-23017-7
Online ISBN: 978-3-319-23018-4
eBook Packages: MedicineMedicine (R0)